Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tivirapine
- Development stage
- Phase 2
- Modality
- Small Molecules
01
Overview
Tivirapine is a small molecule, benzodiazepine non-nucleoside reverse transcriptase inhibitor (NNRTI) that demonstrates activity against human immunodeficiency viruses 1 and 2 (HIV-1 and HIV-2), as well as simian immunodeficiency virus. It functions by inhibiting the replication of these viruses, including both wild-type and drug-resistant HIV-1 isolates. The drug has progressed to a maximum of Phase II clinical trials.
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on Tivirapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tivirapine.